Monoclonal antibodies are the building blocks of some of the most important medical treatments in the world. But they have limitations. For example, the large size of the molecules mean monoclonal antibody treatments usually need to be injected — even for eye conditions. Narval CEO Jose Luis Nuno describes the first time he saw a patient get injected in the eye to treat diabetic retinopathy, a condition that can lead to blindness. “It costs $2,000 every month, you need to get one per month, so it’s very expensive, very difficult and of course painful to be injected there,” he said….